https://kstockbriefing.com
![[Disclosure] Celltrion (068270) – Additional Listing (Stock Option Exercise) / 2024-08-08](https://kstockbriefing.com/wp-content/uploads/2026/08/포맷변환셀트리온.jpg)
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced the additional listing of 27,967 new common shares on August 13, 2024, issued following the exercise of stock options. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Total Issued Shares and Stock Quantity Changes Post-Listing This…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion reported its provisional Q2 2024 separate financial results, recording revenue of approximately KRW 973.2B and operating profit of approximately KRW 313.1B, representing a 987.57% QoQ increase in operating profit. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Comparison Between…
Read More “[Disclosure] Celltrion (068270) – Provisional Sales Results / 2024-08-07” »
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion reported its provisional Q2 2024 consolidated financial results, recording revenue of approximately KRW 874.7B and operating profit of approximately KRW 72.5B, representing a 369.57% QoQ increase in operating profit. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of…
![[Disclosure] ALTEOGEN (196170) – Execution of Joint Development and License Agreement for Hyaluronidase / 2024-07-30](https://kstockbriefing.com/wp-content/uploads/2026/08/포맷변환알테오젠.jpg)
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen executed a joint development and license agreement with Swiss pharmaceutical firm Sandoz AG for a novel hyaluronidase distinct from ALT-B4, under which Alteogen will receive milestone payments and running royalties based on net sales upon commercialization. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen mutually agreed with Sandoz AG to terminate the existing ALT-B4 license agreement and receive returned rights, concurrently executing a new joint development and license agreement for a different hyaluronidase. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Why Verifying…
![[Disclosure] Samsung Biologics (207940) – Major Management Matters (Correction) / 2024-07-30](https://kstockbriefing.com/wp-content/uploads/2026/07/포맷변환-삼성바이오로직스.jpg)
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics announced an amendment modifying both the contract period end date and the non-disclosure deadline for a contract manufacturing LOI signed with a European pharmaceutical company to August 31, 2024. 📊 [Key Disclosure Details & Summary Statistics] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Tracking…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics announced an amendment modifying both the contract period end date and the non-disclosure deadline for a contract manufacturing LOI signed with a European pharmaceutical company to August 31, 2024. 📊 [Key Disclosure Details & Summary Statistics] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Tracking…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics reported its provisional Q2 2024 consolidated financial results, recording revenue of approximately KRW 1.157T and operating profit of KRW 434.5B, up 33.56% and 71.45% year-over-year, respectively. 📊 [Key Disclosure Details & Summary Statistics] (Unit: KRW Million) 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued an advance notice indicating that it plans to release its cumulative Q2 2024 financial results on July 24, 2024. 📊 [Key Disclosure Details & Summary Statistics] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Confirmed Figures and Official Materials on Earnings…
Read More “[Disclosure] Samsung Biologics (207940) – Preview of Financial Results / 2024-07-10” »
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen obtained final marketing authorization approval from the Ministry of Food and Drug Safety (MFDS) for Tergase Injection (ALT-BB4, berahyaluronidase alfa), a recombinant human hyaluronidase stand-alone product. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Why Verifying Marketing Authorization Approval…